RU2019109011A - Композиции и способы с использованием фармакогеномного маркера - Google Patents
Композиции и способы с использованием фармакогеномного маркера Download PDFInfo
- Publication number
- RU2019109011A RU2019109011A RU2019109011A RU2019109011A RU2019109011A RU 2019109011 A RU2019109011 A RU 2019109011A RU 2019109011 A RU2019109011 A RU 2019109011A RU 2019109011 A RU2019109011 A RU 2019109011A RU 2019109011 A RU2019109011 A RU 2019109011A
- Authority
- RU
- Russia
- Prior art keywords
- sequencing
- reagent
- snps
- treatment
- snp
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 35
- 239000003550 marker Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002974 pharmacogenomic effect Effects 0.000 title 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 38
- 238000012163 sequencing technique Methods 0.000 claims 38
- 108091033319 polynucleotide Proteins 0.000 claims 22
- 102000040430 polynucleotide Human genes 0.000 claims 22
- 239000002157 polynucleotide Substances 0.000 claims 22
- 230000000295 complement effect Effects 0.000 claims 21
- DQYBRTASHMYDJG-UHFFFAOYSA-N Bisindolylmaleimide Chemical compound C1=CC=C2C(C=3C(=O)NC(C=3C=3C4=CC=CC=C4NC=3)=O)=CNC2=C1 DQYBRTASHMYDJG-UHFFFAOYSA-N 0.000 claims 12
- 238000004458 analytical method Methods 0.000 claims 12
- 239000012472 biological sample Substances 0.000 claims 12
- 239000000090 biomarker Substances 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 229940043355 kinase inhibitor Drugs 0.000 claims 9
- 239000003909 protein kinase inhibitor Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 230000003321 amplification Effects 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims 8
- 108020004414 DNA Proteins 0.000 claims 7
- 102000054765 polymorphisms of proteins Human genes 0.000 claims 7
- 108090000315 Protein Kinase C Proteins 0.000 claims 6
- 102000003923 Protein Kinase C Human genes 0.000 claims 6
- 238000009396 hybridization Methods 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 238000003752 polymerase chain reaction Methods 0.000 claims 6
- 239000000758 substrate Substances 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 238000001712 DNA sequencing Methods 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 4
- 238000002405 diagnostic procedure Methods 0.000 claims 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000007834 ligase chain reaction Methods 0.000 claims 4
- 238000004949 mass spectrometry Methods 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- AXRCEOKUDYDWLF-UHFFFAOYSA-N 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione Chemical group C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 claims 3
- KIWODJBCHRADND-UHFFFAOYSA-N 3-anilino-4-[1-[3-(1-imidazolyl)propyl]-3-indolyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=CC=C3N(CCCN3C=NC=C3)C=2)=C1NC1=CC=CC=C1 KIWODJBCHRADND-UHFFFAOYSA-N 0.000 claims 3
- 206010008796 Chromaturia Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 229950002189 enzastaurin Drugs 0.000 claims 3
- -1 4EBP1 Proteins 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 101100273253 Rhizopus niveus RNAP gene Proteins 0.000 claims 2
- 102000003861 Ribosomal protein S6 Human genes 0.000 claims 2
- 108090000221 Ribosomal protein S6 Proteins 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000005251 capillar electrophoresis Methods 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000006073 displacement reaction Methods 0.000 claims 2
- 239000003596 drug target Substances 0.000 claims 2
- 238000000840 electrochemical analysis Methods 0.000 claims 2
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 238000001976 enzyme digestion Methods 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 238000012165 high-throughput sequencing Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000011901 isothermal amplification Methods 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000386 microscopy Methods 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 239000002077 nanosphere Substances 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000012175 pyrosequencing Methods 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 108091008146 restriction endonucleases Proteins 0.000 claims 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims 2
- 238000005096 rolling process Methods 0.000 claims 2
- 238000007480 sanger sequencing Methods 0.000 claims 2
- 239000004065 semiconductor Substances 0.000 claims 2
- 238000007841 sequencing by ligation Methods 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 230000005641 tunneling Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 101710105094 Cyclic AMP-responsive element-binding protein Proteins 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000008236 biological pathway Effects 0.000 claims 1
- 102000036109 cAMP binding proteins Human genes 0.000 claims 1
- 108091010966 cAMP binding proteins Proteins 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 238000001962 electrophoresis Methods 0.000 claims 1
- 238000001502 gel electrophoresis Methods 0.000 claims 1
- 238000003205 genotyping method Methods 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000000101 novel biomarker Substances 0.000 claims 1
- 238000003499 nucleic acid array Methods 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382734P | 2016-09-01 | 2016-09-01 | |
| US62/382,734 | 2016-09-01 | ||
| US201662414601P | 2016-10-28 | 2016-10-28 | |
| US62/414,601 | 2016-10-28 | ||
| PCT/US2017/049747 WO2018045240A1 (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019109011A true RU2019109011A (ru) | 2020-10-05 |
| RU2019109011A3 RU2019109011A3 (enExample) | 2021-01-22 |
Family
ID=59923555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019109011A RU2019109011A (ru) | 2016-09-01 | 2017-08-31 | Композиции и способы с использованием фармакогеномного маркера |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11421280B2 (enExample) |
| EP (1) | EP3507384B1 (enExample) |
| JP (3) | JP7197915B2 (enExample) |
| KR (1) | KR20190046935A (enExample) |
| CN (1) | CN109952383B (enExample) |
| AU (1) | AU2017318669B2 (enExample) |
| BR (1) | BR112019003951A2 (enExample) |
| CA (1) | CA3035386A1 (enExample) |
| JO (1) | JOP20190025A1 (enExample) |
| MX (1) | MX2019002377A (enExample) |
| PH (1) | PH12019500422A1 (enExample) |
| RU (1) | RU2019109011A (enExample) |
| SG (2) | SG11201901762WA (enExample) |
| TW (2) | TW202313973A (enExample) |
| WO (1) | WO2018045240A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
| CN110496223B (zh) * | 2018-05-17 | 2021-09-10 | 复旦大学附属肿瘤医院 | 一种治疗非霍奇金氏淋巴瘤的药物组合物 |
| EP3849559A4 (en) * | 2018-09-12 | 2022-06-01 | Denovo Biopharma LLC | COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF |
| CN111549033B (zh) * | 2020-06-11 | 2021-02-12 | 南京市江宁医院 | 慢病毒感染人表皮角质细胞株及其构建方法和应用 |
| US11227690B1 (en) * | 2020-09-14 | 2022-01-18 | Opendna Ltd. | Machine learning prediction of therapy response |
| US20240321421A1 (en) * | 2021-07-23 | 2024-09-26 | Kaohsiung Medical University | Clinical therapeutic drug prediction and recommendation system and method for evaluating efficacy of second-generation hormone drug in treatment of prostate cancer |
| US20230131677A1 (en) * | 2021-10-21 | 2023-04-27 | Toyota Research Institute, Inc. | Systems and methods for predicting the effect of an intervention via machine learning |
| WO2023097197A2 (en) * | 2021-11-23 | 2023-06-01 | Denovo Biopharma Llc | Compositions and methods for assessing the efficacy of polynucleotide delivery and cancer therapy |
| US12474842B2 (en) * | 2021-12-13 | 2025-11-18 | Google Llc | Optimizing data placement based on data temperature and lifetime prediction |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE456367T1 (de) | 1993-12-23 | 2010-02-15 | Lilly Co Eli | Proteinkinase c inhibitoren |
| AU2001285047A1 (en) * | 2000-08-16 | 2002-02-25 | Chiron Corporation | Human genes and gene expression products |
| US20040072217A1 (en) | 2002-06-17 | 2004-04-15 | Affymetrix, Inc. | Methods of analysis of linkage disequilibrium |
| CA2393720C (en) | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| US20080299125A1 (en) | 2006-06-05 | 2008-12-04 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| JP2014506459A (ja) | 2011-01-31 | 2014-03-17 | デノボ バイオマーカーズ インコーポレイテッド | 薬理ゲノミクスバイオマーカーを発見するための方法 |
| CA2838207A1 (en) | 2011-06-08 | 2012-12-13 | Denovo Biopharma (Hangzhou) Ltd. Co. | Methods and compositions of predicting activity of retinoid x receptor modulator |
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
-
2017
- 2017-06-16 JO JOP/2019/0025A patent/JOP20190025A1/ar unknown
- 2017-08-31 KR KR1020197009407A patent/KR20190046935A/ko not_active Ceased
- 2017-08-31 EP EP17771623.0A patent/EP3507384B1/en active Active
- 2017-08-31 US US16/327,788 patent/US11421280B2/en active Active
- 2017-08-31 RU RU2019109011A patent/RU2019109011A/ru unknown
- 2017-08-31 CA CA3035386A patent/CA3035386A1/en active Pending
- 2017-08-31 CN CN201780066737.5A patent/CN109952383B/zh active Active
- 2017-08-31 JP JP2019512609A patent/JP7197915B2/ja active Active
- 2017-08-31 MX MX2019002377A patent/MX2019002377A/es unknown
- 2017-08-31 SG SG11201901762WA patent/SG11201901762WA/en unknown
- 2017-08-31 TW TW111122709A patent/TW202313973A/zh unknown
- 2017-08-31 AU AU2017318669A patent/AU2017318669B2/en not_active Ceased
- 2017-08-31 BR BR112019003951A patent/BR112019003951A2/pt not_active IP Right Cessation
- 2017-08-31 WO PCT/US2017/049747 patent/WO2018045240A1/en not_active Ceased
- 2017-08-31 TW TW106129838A patent/TWI771317B/zh not_active IP Right Cessation
- 2017-08-31 SG SG10201912134TA patent/SG10201912134TA/en unknown
-
2019
- 2019-02-27 PH PH12019500422A patent/PH12019500422A1/en unknown
-
2020
- 2020-08-26 JP JP2020142358A patent/JP2020188816A/ja active Pending
-
2022
- 2022-08-18 US US17/820,772 patent/US20230074781A1/en not_active Abandoned
- 2022-09-16 JP JP2022148064A patent/JP2022173308A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3507384A1 (en) | 2019-07-10 |
| CN109952383B (zh) | 2024-01-05 |
| JOP20190025A1 (ar) | 2019-02-19 |
| KR20190046935A (ko) | 2019-05-07 |
| CN109952383A (zh) | 2019-06-28 |
| WO2018045240A1 (en) | 2018-03-08 |
| SG10201912134TA (en) | 2020-02-27 |
| PH12019500422A1 (en) | 2019-05-27 |
| MX2019002377A (es) | 2019-09-05 |
| US20190233902A1 (en) | 2019-08-01 |
| SG11201901762WA (en) | 2019-03-28 |
| JP2019528705A (ja) | 2019-10-17 |
| TWI771317B (zh) | 2022-07-21 |
| JP2020188816A (ja) | 2020-11-26 |
| US20230074781A1 (en) | 2023-03-09 |
| EP3507384B1 (en) | 2023-08-30 |
| CA3035386A1 (en) | 2018-03-08 |
| TW201812125A (zh) | 2018-04-01 |
| JP2022173308A (ja) | 2022-11-18 |
| US11421280B2 (en) | 2022-08-23 |
| RU2019109011A3 (enExample) | 2021-01-22 |
| AU2017318669A1 (en) | 2019-03-07 |
| TW202313973A (zh) | 2023-04-01 |
| BR112019003951A2 (pt) | 2019-06-25 |
| AU2017318669B2 (en) | 2023-04-20 |
| JP7197915B2 (ja) | 2022-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019109011A (ru) | Композиции и способы с использованием фармакогеномного маркера | |
| Wang et al. | Single cell sequencing: a distinct new field | |
| Reeser et al. | Validation of a targeted RNA sequencing assay for kinase fusion detection in solid tumors | |
| JP2019528705A5 (enExample) | ||
| JP2021503943A5 (enExample) | ||
| US10100351B2 (en) | High-throughput sequencing detection method for methylated CpG islands | |
| US20140045706A1 (en) | Methods and systems for haplotype determination | |
| US20150087535A1 (en) | Measurement of nucleic acid variants using highly-multiplexed error-suppressed deep sequencing | |
| JP2019520037A5 (enExample) | ||
| US20140017683A1 (en) | Method for single cell genome analysis and kit therefor | |
| EP3105324B1 (en) | Ngs systems control and methods involving the same | |
| CN105274190A (zh) | 一种检测cyp3a4*1g和mdr1c1236t的基因多态性的hrm方法 | |
| US20160208240A1 (en) | Ngs workflow | |
| Wakimoto et al. | Isolation of Single‐Stranded DNA | |
| US20200040390A1 (en) | Methods for Sequencing Repetitive Genomic Regions | |
| WO2015189685A2 (en) | Improved ngs workflow | |
| Latini et al. | An overview of the use of SNaPshot for predicting blood group antigens | |
| RU2609641C1 (ru) | Способ анализа соматических мутаций в химерном гене BCR/ABL с использованием ОТ-ПЦР и последующей гибридизацией с олигонуклеотидным биологическим микрочипом (биочипом) | |
| Sa'adah et al. | A rapid, accurate and simple screening method for spinal muscular atrophy: high-resolution melting analysis using dried blood spots on filter paper | |
| RU2549682C1 (ru) | Способ анализа соматических мутаций в гене pi3k с использованием lna-блокирующей мультиплексной пцр и последующей гибридизацией с олигонуклеотидным биологическим микрочипом (биочипом) | |
| Nguyen-Dumont et al. | Hi-Plex targeted sequencing is effective using DNA derived from archival dried blood spots | |
| KR101136008B1 (ko) | 옥사닌 염기를 포함한 라이게이션 단편서열을 이용한 리가제 기반 단일염기다형성 분석방법 및 그 단편서열을 포함하는 단일염기다형성 분석용 시스템 | |
| JP2005323565A (ja) | 標的ｄｎａ配列において一塩基変異多型の存在を検出する方法及びキット | |
| Ng et al. | Spatially addressable bead-based biosensor for rapid detection of beta-thalassemia mutations | |
| KR101700622B1 (ko) | 개의 품종 식별을 위한 dna 마커 및 이를 이용한 개 품종 식별방법 |